Kiniksa Pharmaceuticals, Ltd. - (KNSA) News
Filter KNSA News Items
KNSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KNSA News Highlights
- For KNSA, its 30 day story count is now at 2.
- Over the past 8 days, the trend for KNSA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest KNSA News From Around the Web
Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), has sold 9,316 shares of the company on December 19, 2023, according to a recent SEC Filing. |
The 3 Most Undervalued Biotech Stocks to Buy in DecemberBiotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. |
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's HowKiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates. |
Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 70.3% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
7 Underappreciated Biotech Stocks to Pick Up on the CheapAmid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. |
Here's Why We're Not At All Concerned With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call TranscriptKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please […] |
Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings CallQ3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue EstimatesKiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -11.11% and 7.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of |